Oncrasin targets the JNK-NF-κb axis to sensitize glioma cells to TNFα-induced apoptosis

Carcinogenesis

Volumn 34, Issue 2, 2013, Pages 388-396

  Gupta, Piyushi ^a   Dixit, Deobrat ^a   Sen, Ellora ^a  

^a NATIONAL BRAIN RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 8; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ONCRASIN; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TELOMERASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; DNA DAMAGE; ENZYME ACTIVATION; ENZYME INHIBITION; GLIOMA CELL; HUMAN; HUMAN CELL; NUCLEOSOME; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTIGENS, CD95; APOPTOSIS; BLOTTING, WESTERN; CASPASE 8; CELL CYCLE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; FLOW CYTOMETRY; GLIOBLASTOMA; HMGB1 PROTEIN; HUMANS; IMMUNOPRECIPITATION; INDOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LUCIFERASES; NF-KAPPA B; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TELOMERASE; TUMOR NECROSIS FACTOR-ALPHA; TUMOR STEM CELL ASSAY;

EID: 84873550822     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs352     Document Type: Article

References (50)

1. Nozell,S. et al. (2008) The ING4 tumor suppressor attenuates NF-kappaB activity at the promoters of target genes. Mol. Cell. Biol., 28, 6632-6645.
2. Robe,P.A. et al. (2004) In vitro and in vivo activity of the nuclear factorkappaB inhibitor sulfasalazine in human glioblastomas. Clin. Cancer Res., 10, 5595-5603.
3. Aggarwal,B.B. (2004) Nuclear factor-kappaB: the enemy within. Cancer Cell, 6, 203-208.
4. Sen,E. (2011) Targeting inflammation-induced transcription factor activation: an open frontier for glioma therapy. Drug Discov. Today, 16, 1044-1051.
5. Tsujimoto,M. et al. (1985) Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells. Proc. Natl. Acad. Sci. U.S.A., 82, 7626-7630.
6. Beg,A.A. et al. (1996) An essential role for NF-kappaB in preventing TNFalpha-induced cell death. Science, 274, 782-784.
7. Wang,C.Y. et al. (1996) TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science, 274, 784-787.
8. Sharma,V. et al. (2008) Ebselen sensitizes glioblastoma cells to tumor necrosis factor (TNFalpha)-induced apoptosis through two distinct pathways involving NF-kappaB downregulation and Fas-mediated formation of death inducing signaling complex. Int. J. Cancer, 123, 2204-2212.
9. Dixit,D. et al. (2012) Inhibition of casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition. Cell Death Dis., 3, e271.
10. Feldkamp,M.M. et al. (1999) Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery, 45, 1442-1453.
11. Finco,T.S. et al. (1997) Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J. Biol. Chem., 272, 24113-24116.
12. Norris,J.L. et al. (1999) Oncogenic Ras enhances NF-kappaB transcriptional activity through Raf-dependent and Raf-independent mitogen-activated protein kinase signaling pathways. J. Biol. Chem., 274, 13841-13846.
13. Lee,H. et al. (2009) Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell, 15, 283-293.
14. Rahaman,S.O. et al. (2002) Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene, 21, 8404-8413.
15. Gough,D.J. et al. (2009) Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science, 324, 1713-1716.
16. Guo,W. et al. (2008) Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res., 68, 7403-7408.
17. Tang,F. et al. (2002) The absence of NF-kappaB-mediated inhibition of c-Jun N-terminal kinase activation contributes to tumor necrosis factor alpha-induced apoptosis. Mol. Cell. Biol., 22, 8571-8579.
18. Tang,G. et al. (2001) Inhibition of JNK activation through NF-kappaB target genes. Nature, 414, 313-317.
19. Kennedy,N.J. et al. (2003) Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Genes Dev., 17, 629-637.
20. Sharma,V. et al. (2010) HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity. J. Cell Mol. Med., 14, 2151-2161.
21. Koul,N. et al. (2010) Bicyclic triterpenoid Iripallidal induces apoptosis and inhibits Akt/mTOR pathway in glioma cells. BMC Cancer, 10, 328.
22. Sharma,V. et al. (2011) Ras regulates interleukin-1β-induced HIF-1α transcriptional activity in glioblastoma. J. Mol. Med., 89, 123-136.
23. Tewari,R. et al. (2008) Involvement of miltefosine-mediated ERK activation in glioma cell apoptosis through Fas regulation. J. Neurochem., 107, 616-627.
24. Dixit,D. et al. (2009) Manumycin inhibits STAT3, telomerase activity, and growth of glioma cells by elevating intracellular reactive oxygen species generation. Free Radic. Biol. Med., 47, 364-374.
25. Safrit,J.T. et al. (1992) Sensitivity of resistant human tumor cell lines to tumor necrosis factor and adriamycin used in combination: correlation between down-regulation of tumor necrosis factor-messenger RNA induction and overcoming resistance. Cancer Res., 52, 6630-6637.
26. Zhang,X. et al. (1999) Telomere shortening and apoptosis in telomeraseinhibited human tumor cells. Genes Dev., 13, 2388-2399.
27. Mukai,S. et al. (2000) 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res., 60, 4461-4467.
28. Candolfi,M. et al. (2009) Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin. Cancer Res., 15, 4401-4414.
29. Urbonaviciute,V. et al. (2008) Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med., 205, 3007-3018.
30. Ashkenazi,A. (2002) Targeting death and decoy receptors of the tumournecrosis factor superfamily. Nat. Rev. Cancer, 2, 420-430.
31. Lange,S.S. et al. (2008) High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage. Proc. Natl. Acad. Sci. U.S.A., 105, 10320-10325.
32. Lavin,M.F. et al. (2007) ATM activation and DNA damage response. Cell Cycle, 6, 931-942.
33. Häcker,H. et al. (2006) Regulation and function of IKK and IKK-related kinases. Sci. STKE, 2006, re13.
34. Xia,S. et al. (2007) Ribotoxic stress sensitizes glioblastoma cells to death receptor induced apoptosis: requirements for c-Jun NH2-terminal kinase and Bim. Mol. Cancer Res., 5, 783-792.
35. Jin,H.O. et al. (2006) Up-regulation of Bak and Bim via JNK downstream pathway in the response to nitric oxide in human glioblastoma cells. J. Cell. Physiol., 206, 477-486.
36. Minden,A. et al. (1994) Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science, 266, 1719-1723.
37. Guo,W. et al. (2011) Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition. PLoS ONE, 6, e28487.
38. Liu,H. et al. (2002) NF-kappaB inhibition sensitizes hepatocytes to TNF-induced apoptosis through a sustained activation of JNK and c-Jun. Hepatology, 35, 772-778.
39. Schroeter,H. et al. (2003) c-Jun N-terminal kinase (JNK)-mediated modulation of brain mitochondria function: new target proteins for JNK signalling in mitochondrion-dependent apoptosis. Biochem. J., 372(Pt 2), 359-369.
40. Zhang,S. et al. (2004) Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNFalpha-induced apoptosis in human cancer cells. Carcinogenesis, 25, 2191-2199.
41. Shimada,K. et al. (2003) c-Jun NH2-terminal kinase-dependent Fas activation contributes to etoposide-induced apoptosis in p53-mutated prostate cancer cells. Prostate, 55, 265-280.
42. Shimada,K. et al. (2004) Phosphorylation of FADD is critical for sensitivity to anticancer drug-induced apoptosis. Carcinogenesis, 25, 1089-1097.
43. Kesanakurti,D. et al. (2011) Suppression of MMP-2 attenuates TNF-α induced NF-κB activation and leads to JNK mediated cell death in glioma. PLoS ONE, 6, e19341.
44. Lo,H.W. et al. (2008) Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin. Cancer Res., 14, 6042-6054.
45. Mamay,C.L. et al. (2003) An inhibitory function for JNK in the regulation of IGF-I signaling in breast cancer. Oncogene, 22, 602-614.
46. Deng,Y. et al. (2003) A JNK-dependent pathway is required for TNFalphainduced apoptosis. Cell, 115, 61-70.
47. Antonyak,M.A. et al. (2002) Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene, 21, 5038-5046.
48. Atkinson,G.P. et al. (2010) NF-kappaB and STAT3 signaling in glioma: targets for future therapies. Expert Rev. Neurother., 10, 575-586.
49. Qin,Y. et al. (2002) Fas resistance of leukemic eosinophils is due to activation of NF-kappa B by Fas ligation. J. Immunol., 169, 3536-3544.
50. Kim,J.H. et al. (2010) Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines. Biochem. Pharmacol., 79, 373-380.